Literature DB >> 24314341

Comparative effectiveness research: opportunities in surgical oncology.

Heather B Neuman1, Caprice C Greenberg.   

Abstract

Comparative effectiveness research (CER) is especially applicable to surgical oncology because of the numerous challenges associated with conducting surgical randomized controlled trials, and the opportunity to apply various CER methodologies to answer surgical questions. In this article, several past randomized trials or attempted trials are described to demonstrate challenges related to feasibility, patient selection and generalizability, and timeliness trial results to inform clinical practice. Thus, there is a gap between these "efficacy" studies (ie, randomized trials) and "effectiveness" research, which is performed in a less controlled setting (not randomized) but is able to examine patient outcomes in the "real world." Retrospective analyses and pragmatic trials are other important methods for answering CER questions in surgical oncology, with examples of these studies being conducted in prostate, breast, and rectal cancers. Multiple current initiatives by the American College of Surgeons and the Alliance for Clinical Trials in Oncology continue to expand the infrastructure for CER in surgical oncology.
© 2013 Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24314341     DOI: 10.1016/j.semradonc.2013.09.003

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  2 in total

1.  CaPTHUS scoring model in primary hyperparathyroidism: can it eliminate the need for ioPTH testing?

Authors:  Dawn M Elfenbein; Sara Weber; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2014-09-12       Impact factor: 5.344

2.  Ethical tensions in the informed consent process for randomized clinical trials in emergency obstetric and newborn care in low and middle-income countries.

Authors:  Dan K Kaye; Gershom Chongwe; Nelson K Sewankambo
Journal:  BMC Med Ethics       Date:  2019-04-27       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.